Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates
Sign Up to like & getrecommendations! Published in 2017 at "Drug Delivery and Translational Research"
DOI: 10.1007/s13346-017-0472-6
Abstract: Elacridar (GF120918) is a highly potent inhibitor of both P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), the main efflux transporters expressed at the blood-brain barrier (BBB). Elacridar shows very low aqueous solubility, which complicates… read more here.
Keywords: controlled exposure; elacridar; infusion; intravenous infusion ... See more keywords
Evidence That P-glycoprotein Inhibitor (Elacridar)-Loaded Nanocarriers Improve Epidermal Targeting of an Anticancer Drug via Absorptive Cutaneous Transporters Inhibition.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of pharmaceutical sciences"
DOI: 10.1016/j.xphs.2017.09.007
Abstract: Because P-glycoprotein (P-gp) plays an absorptive role in the skin, its pharmacological inhibition represents a strategy to promote cutaneous localization of anticancer agents that serve as its substrates, improving local efficacy while reducing systemic exposure.… read more here.
Keywords: inhibitor elacridar; elacridar; elacridar loaded; drug ... See more keywords
Abstract 418: Elacridar potentiates sunitinib efficacy in colorectal cancer models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-418
Abstract: For unresectable metastatic colorectal cancer (mCRC), the main treatment strategy is combination chemotherapy, targeted therapy, or immunotherapy. Long-term treatment benefit of these therapies is limited to a small subgroup of patients. To improve treatment outcome,… read more here.
Keywords: elacridar; colorectal cancer; elacridar potentiates; cancer ... See more keywords
The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1129832
Abstract: Introduction Paclitaxel (PTX) interferes with microtubule architecture by binding to β-tubulin, thereby blocking progression at the G2/M phase and inducing apoptosis. This study aimed to investigate molecular processes underlying PTX-mediated resistance in gastric cancer (GC)… read more here.
Keywords: mediated resistance; ptx; ramucirumab; elacridar ... See more keywords
Investigations with Drugs and Pesticides Revealed New Species- and Substrate-Dependent Inhibition by Elacridar and Imazalil in Human and Mouse Organic Cation Transporter OCT2
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms232415795
Abstract: Multiple drugs are used to treat various indications as well as pesticides that are ingested unintentionally and enter the bloodstream. The residence time or bioavailability of these substances in circulation depends on several mechanisms, such… read more here.
Keywords: inhibition; transporter; elacridar; imazalil ... See more keywords